A randomized, phase 1, placebo-controlled trial of APG-157 in oral cancer demonstrates systemic absorption and an inhibitory effect on cytokines and tumor-associated microbes.
Saroj K BasakAlakesh BeraAlexander J YoonMarco MorselliChan JeongAnela TosevskaTien S DongMichael EklundEric RussHassan NasserVenu LagishettyRong GuoDipti SajedSharmila MudgalParag MehtaLuis AvilaMeera SrivastavaKym FaullJonathan JacobsMatteo PellegriniDaniel Sanghoon ShinEri S SrivatsanMarilene B WangPublished in: Cancer (2020)
Curcumin has been shown to suppress tumor cells because of its antioxidant and anti-inflammatory properties. However, its effectiveness has been limited by poor absorption when delivered orally. Subjects with oral cancer were given oral APG-157, a botanical drug containing multiple polyphenols, including curcumin. Curcumin was found in the blood and in tumor tissues. Inflammatory markers and Bacteroides species were found to be decreased in the saliva, and immune T cells were increased in the tumor tissue. APG-157 is absorbed well, reduces inflammation, and attracts T cells to the tumor, suggesting its potential use in combination with immunotherapy drugs.